CIViC Evidence Items

265 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
C	EGFR	L838P	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	de Gunst et al., 2007
D	EGFR	S768I	Predictive	Does Not Support	Sensitivity/Response	Cancer	Erlotinib,Gefitinib	Kancha et al., 2009
D	EGFR	R831H	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Yasuda et al., 2013
C	EGFR	L858R	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Crizotinib	Doebele et al., 2012
D	EGFR	L858R	Predictive	Does Not Support	Sensitivity/Response	Lung Adenocarcinoma	Cetuximab	Konduri et al., 2016
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Erlotinib	Lee et al., 2006
B	EGFR	L861	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Gefitinib	Wu et al., 2011
D	EGFR	L861Q	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Erlotinib	Lee et al., 2006
D	EGFR	E868G	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
C	EGFR	H773_V774insNPH	Predictive	Supports	Resistance	Lung Adenocarcinoma	Erlotinib	Yasuda et al., 2013
D	EGFR	VIII	Predictive	Supports	Sensitivity/Response	High Grade Glioma	Erlotinib	Lee et al., 2006
D	EGFR	W731L	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
D	EGFR	E734Q	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
D	EGFR	T785A	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
D	EGFR	C797Y	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
D	EGFR	Y801H	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
C	EGFR	L747_S752delinsQ	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Pao et al., 2004
C	EGFR	L861R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Wu et al., 2011
C	EGFR	P772_H773insYNP	Predictive	Supports	Resistance	Lung Non-small Cell Carcinoma	Erlotinib	Yasuda et al., 2013
C	EGFR	P772_V774insPHV	Predictive	Does Not Support	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Yasuda et al., 2013
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib,Dacomitinib	Ramalingam et al., 2016
B	EGFR	Expression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib	Fukuoka et al., 2003
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Foster et al., 2010
C	EGFR	M766_A767insASV	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Erlotinib	Yasuda et al., 2013
D	EGFR	D770_N771insNPG	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib,Gefitinib	Yasuda et al., 2013
C	EGFR	L747_P753delinsS	Predictive	Supports	Sensitivity/Response	Pancreatic Adenocarcinoma	Erlotinib	Cecchini et al., 2017
B	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Urata et al., 2016
C	EGFR	A767_V769dupASV	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Fang et al., 2019
C	EGFR	D770_N771insG	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Fang et al., 2019
C	EGFR	S768_D770dup	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib	Fang et al., 2019
D	EGFR	G598V	Predictive	Supports	Sensitivity/Response	Cancer	Erlotinib	Lee et al., 2006
D	EGFR	S645C	Oncogenic	Supports	Oncogenicity	Lung Cancer		Berger et al., 2016
D	EGFR	K754E	Oncogenic	Supports	Oncogenicity	Lung Cancer		Berger et al., 2016
A	EGFR	S768I OR EGFR G719A OR EGFR L861Q	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Afatinib	Yang et al., 2012
C	EGFR	Amplification AND EGFR EGFRVIII	Predictive	Supports	Sensitivity/Response	Glioblastoma	Afatinib	Alshami et al., 2015
B	EGFR	VIII	Predictive	Supports	Resistance	Head And Neck Squamous Cell Carcinoma	Docetaxel,Cetuximab	Tinhofer et al., 2011
D	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Banno et al., 2015
B	EGFR	Exon 18 Overexpression	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Bevacizumab,Erlotinib	Baty et al., 2013
D	EGFR	T790M	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Osimertinib,Rociletinib	Hirano et al., 2015
D	EGFR	L858R	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Hirano et al., 2015
D	EGFR	Exon 19 Deletion	Predictive	Supports	Sensitivity/Response	Lung Non-small Cell Carcinoma	Afatinib	Hirano et al., 2015
B	EGFR	Amplification	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Gefitinib,Erlotinib	Fiala et al., 2016
C	EGFR	S492R	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab	Montagut et al., 2012
D	EGFR	R451C	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Cetuximab,Panitumumab,Futuximab/Modotuximab Mixture	Sánchez-Martín et al., 2016
C	EGFR	S768I	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Gefitinib	Masago et al., 2010
B	EGFR	Expression	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Panitumumab	Van Cutsem et al., 2007
B	EGFR	G719	Predictive	Supports	Sensitivity/Response	Lung Adenocarcinoma	Erlotinib	Klughammer et al., 2016
B	EGFR	Expression	Predictive	Supports	Sensitivity/Response	Chordoma	Lapatinib	Stacchiotti et al., 2013

Page 4 of 6

Previous Next